At this point I think Missling needs to figure out how to license the use of A2-73/3-71 for different indications.
Sure we can launch with Rett or PD, but the necessary research and trial time needed to fully understand the benefits and limitations are way too expansive for Anavex (at this point in time).
If the Anavex portfolio is as truly gifted as we all hope for, then Missling needs to figure out a way to commercialize these assets, both for the health of the company as well as patients. To me waiting 10 more years isn't acceptable. In five years Anavex needs to be at least in the $10B market cap range.